Clinical Trial Update: A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on RUBY, a Phase 1/2 clinical trial evaluating EDIT-301 for severe sickle cell disease, focusing on safety and efficacy endpoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemoglobinopathy
• Sickle Cell Disease

Drugs mentioned

• EDIT-301

Snippet

Sponsor: Editas Medicine, Inc. | Conditions: Sickle Cell Disease, Hemoglobinopathies | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING